Edwards Lifesciences Corporation $EW Shares Bought by Cwm LLC

Cwm LLC boosted its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW) by 24.1% during the second quarter, Holdings Channel.com reports. The institutional investor owned 40,851 shares of the medical research company’s stock after buying an additional 7,935 shares during the period. Cwm LLC’s holdings in Edwards Lifesciences were worth $3,195,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the business. OFI Invest Asset Management lifted its holdings in Edwards Lifesciences by 7.0% during the 2nd quarter. OFI Invest Asset Management now owns 339,715 shares of the medical research company’s stock worth $26,569,000 after buying an additional 22,282 shares in the last quarter. Vanguard Personalized Indexing Management LLC lifted its holdings in Edwards Lifesciences by 31.4% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 82,969 shares of the medical research company’s stock worth $6,489,000 after buying an additional 19,826 shares in the last quarter. Concurrent Investment Advisors LLC lifted its holdings in Edwards Lifesciences by 12.9% during the 2nd quarter. Concurrent Investment Advisors LLC now owns 30,390 shares of the medical research company’s stock worth $2,377,000 after buying an additional 3,481 shares in the last quarter. Asset Planning Inc lifted its holdings in Edwards Lifesciences by 3.8% during the 2nd quarter. Asset Planning Inc now owns 27,948 shares of the medical research company’s stock worth $2,186,000 after buying an additional 1,015 shares in the last quarter. Finally, Johnson Investment Counsel Inc. lifted its holdings in Edwards Lifesciences by 8.8% during the 2nd quarter. Johnson Investment Counsel Inc. now owns 9,029 shares of the medical research company’s stock worth $706,000 after buying an additional 734 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Edwards Lifesciences

In related news, VP Daniel J. Lippis sold 4,114 shares of Edwards Lifesciences stock in a transaction on Monday, July 28th. The shares were sold at an average price of $79.46, for a total transaction of $326,898.44. Following the sale, the vice president directly owned 22,002 shares in the company, valued at $1,748,278.92. This trade represents a 15.75% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Larry L. Wood sold 8,950 shares of Edwards Lifesciences stock in a transaction on Monday, August 18th. The stock was sold at an average price of $78.06, for a total transaction of $698,637.00. Following the sale, the insider owned 206,900 shares in the company, valued at $16,150,614. This represents a 4.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.29% of the stock is owned by company insiders.

Edwards Lifesciences Price Performance

Shares of NYSE:EW opened at $74.50 on Friday. The company’s fifty day moving average price is $77.54 and its 200 day moving average price is $76.16. Edwards Lifesciences Corporation has a 12 month low of $64.89 and a 12 month high of $83.00. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.68 and a quick ratio of 3.87. The firm has a market capitalization of $43.74 billion, a P/E ratio of 10.72, a P/E/G ratio of 3.49 and a beta of 1.05.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, topping the consensus estimate of $0.62 by $0.05. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The firm had revenue of $1.53 billion for the quarter, compared to analyst estimates of $1.49 billion. During the same period last year, the business earned $0.70 EPS. Edwards Lifesciences’s revenue for the quarter was up 11.9% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. As a group, sell-side analysts predict that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have issued reports on EW. Wall Street Zen lowered shares of Edwards Lifesciences from a “strong-buy” rating to a “buy” rating in a report on Monday, September 29th. William Blair upgraded shares of Edwards Lifesciences to a “strong-buy” rating in a report on Friday, July 25th. The Goldman Sachs Group restated a “buy” rating on shares of Edwards Lifesciences in a report on Friday, July 25th. Canaccord Genuity Group raised their price objective on shares of Edwards Lifesciences from $75.00 to $81.00 and gave the company a “hold” rating in a report on Friday, July 25th. Finally, Royal Bank Of Canada raised their price objective on shares of Edwards Lifesciences from $85.00 to $89.00 and gave the company an “outperform” rating in a report on Friday, July 25th. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Edwards Lifesciences presently has an average rating of “Moderate Buy” and a consensus target price of $87.06.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.